The global B cell lymphoma-2 (BCL-2) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). B cell lymphoma is termed as a protein encoding gene of the B cell lymphoma family. There have been various inhibitor drugs that are approved in the market which is further likely to spur the market growth. For instance, Venetoclax is the only and fist approved FDA BCL-2 inhibitor drug for chronic lymphocytic lymphoma patients. Although various clinical trials are being carried out for the development of new BCL-2 inhibitors. Further, the market growth is majorly attributable to the growth in the prevalence of diffuse B cell lymphoma, a common type of non-Hodgkin lymphoma. For instance, according to an article by Lymphoma Research Foundation in 2019, in the US, DLBCL accounted for 22% of new diagnosed B cell lymphoma cases. Around 18,000 people globally are diagnosed with DLBCL each year.
To Request a Sample of our Report on B Cell Lymphoma-2 (BCL-2) Inhibitors Market: https://www.omrglobal.com/request-sample/b-cell-lymphoma-2-bcl-2-inhibitors-market
Adding to this, the disease affects people over 60 years of age. According to the American Cancer Society in 2019, an estimated 20,720 people were diagnosed with chronic lymphocytic lymphoma. Moreover, 90% of the people diagnosed with this form of lymphoma are estimated to affect people above 50 years of age. In the US, 2,220 men and 1,710 women are expected to be suffering from chronic lymphocytic lymphoma every year. Moreover, as per the American Cancer Society, about 3,930 mortalities were anticipated to take place in 2019.
Some key players operating in the market include AbbVie Inc. and F. Hoffman La-Roche AG. The market players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Product
- By Indication Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: AbbVie Inc. and F. Hoffman La-Roche AG.
A full Report of B Cell Lymphoma-2 (BCL-2) Inhibitors Market is Available @ https://www.omrglobal.com/industry-reports/b-cell-lymphoma-2-bcl-2-inhibitors-market
Global B Cell Lymphoma-2 (BCL-2) Inhibitors Market Report by Segment
By Product
- Combination Therapy
- Monotherapy
By Indication Type
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Lymphoma (CLL)
- Mantle Cell Lymphoma
- Others
Global B Cell Lymphoma-2 (BCL-2) Inhibitors Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
